Jim Miller

Lessons from the earthquake in Japan show the vulnerability of the bio/pharma supply chain.

Indian manufacturers are not a near-term threat to Western CMOs, but may be long term.

Indian manufacturers are not a near-term threat to Western CMOs, but may be long term.

CDMOs and CMOs face weak economic recovery, consolidation, and globalization.

The designation of preferred partners has become integral to the outsourcing process. Read this and other preferred organization articles in this special issue.

Covance's deal with sanofi-aventis demonstrates the power of scale and scope.

CDMOs and CMOs face weak economic recovery, consolidation, and globalization.

Covance's deal with sanofi-aventis demonstrates the power of scale and scope.

Global pharmaceutical companies could have a problem getting rid of redundant facilities.

Changing demands in drug development lead to new service combinations and models.

Global pharmaceutical companies could have a problem getting rid of redundant facilities.

Changing demands in drug development lead to new service combinations and models.

Rising labor costs in China may result in increased competition for higher value services.

The health of the contract-services industry is improving but the market is signaling tougher competition ahead. This article is part of the 2010 Outsourcing Resources special issue.

The sovereign debt crisis in the EU could greatly change the landscape for contract services.

Rising labor costs in China may result in increased competition for higher value services.

Rising labour rates in China may reduce its cost advantage, but will probably result in western suppliers facing more competition for higher value services.

The sovereign debt crisis in the EU could greatly change the landscape for contract services.

Having barely begun recovering from the economic slump that began in 2008, the contract services industry must now face the consequences of the debt crisis in Europe, which will include reduced bio/pharmaceutical expenditure by governments.

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.

Lilly faces up to the new realities of the bio/pharmaceutical industry by embracing outsourcing.

CMOs' business model has all of the flaws of the captive model it is meant to replace.

CMOs' business model has all of the flaws of the captive model it is meant to replace.

Some predictions for contract services in 2010.

Big Pharma's efforts to reduce working capital will hurt CMOs for years to come.

Some predictions for contract services in 2010.

It's customary among columnists to begin a new year with some predictions about what's to come. We don't honour that custom every year, but with what the contract services industry went through in 2009, it seemed appropriate to share thoughts on what we expect for 2010.

Big Pharma's efforts to reduce working capital will hurt CMOs for years to come.

Contract organizations waiting for the pipeline to come roaring back are kidding themselves.